SCHEMBL9019956

SCHEMBL9019956

Nc1nc2c(ncn2C2CC(CO)C2)c(=O)[nH]1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPRT1 P00492 6/20 0.57
ADORA3 P0DMS8 1/20 0.55
PNP P00491 3/20 0.54
TK1 P04183 2/20 0.51
BLM P54132 2/20 0.50
USP2 O75604 1/20 0.50
TSHR P16473 1/20 0.50
EDNRA P25101 1/20 0.50
HTR2A P28223 1/20 0.50
RECQL P46063 1/20 0.50
HBB P68871 1/20 0.50
HSD17B10 Q99714 1/20 0.50
MEN1 O00255 1/20 0.48
ALDH1A1 P00352 1/20 0.48
LMNA P02545 1/20 0.48
CYP3A4 P08684 1/20 0.48
NFKB1 P19838 1/20 0.48
VCP P55072 1/20 0.48
KMT2A Q03164 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9019958 1.00 HPRT1 (0.57) HPRT1ADORA3PNPTK1BLM
SCHEMBL23721010 0.92 HPRT1 (0.55) HPRT1ADORA3PNPTK1BLM
SCHEMBL10394261 0.92 HPRT1 (0.55) HPRT1ADORA3PNPTK1BLM
SCHEMBL9309680 0.91 HPRT1 (0.58) HPRT1ADORA3PNPTK1BLM
SCHEMBL6538609 0.86 HPRT1 (0.56) HPRT1ADORA3PNPTK1BLM
SCHEMBL1981358 0.86 HPRT1 (0.56) HPRT1ADORA3PNPTK1BLM
SCHEMBL30150327 0.86 HPRT1 (0.56) HPRT1ADORA3PNPTK1BLM
SCHEMBL1981357 0.86 HPRT1 (0.56) HPRT1ADORA3PNPTK1BLM
SCHEMBL21050282 0.86 HPRT1 (0.56) HPRT1ADORA3PNPTK1BLM
SCHEMBL9471250 0.86 PNP (0.57) HPRT1ADORA3PNPTK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0352013-B1 Hydroxymethyl cyclobutyl purines SQUIBB & SONS INC (US) 1996-05-01 EP claimed
US-5369098-A Viricides E. R. SQUIBB & SONS, INC. (US) 1994-11-29 US claimed
EP-0352013-A2 Hydroxymethyl cyclobutyl purines E.R. Squibb & Sons, Inc. (US) 1990-01-24 EP claimed
JP-2073072-A None JP disclosed
US-12202850-B2 Cyclobutyl purine derivative or salt thereof FUJIFILM CORPORATION (JP) 2025-01-21 US disclosed
EP-3831388-B1 CYCLOPENTENYL PURINE DERIVATIVE OR SALT THEREOF FOR USE IN SUPPRESSING ADENOVIRUS FUJIFILM CORP (JP) 2024-02-28 EP disclosed
US-20230295202-A1 CYCLOBUTYL PURINE DERIVATIVE OR SALT THEREOF FUJIFILM CORPORATION (JP) 2023-09-21 US disclosed
EP-3831836-B1 CYCLOBUTYL PURINE DERIVATIVE OR SALT THEREOF FUJIFILM CORP (JP) 2023-09-06 EP disclosed
EP-3831388-A1 CYCLOPENTENYL PURINE DERIVATIVE OR SALT THEREOF FUJIFILM Corporation (JP) 2021-06-09 EP disclosed
EP-3831836-A1 CYCLOBUTYL PURINE DERIVATIVE OR SALT THEREOF FUJIFILM Corporation (JP) 2021-06-09 EP disclosed
US-20210155644-A1 CYCLOPENTENYL PURINE DERIVATIVE OR SALT THEREOF FUJIFILM CORPORATION (JP) 2021-05-27 US disclosed
WO-2020022487-A1 CYCLOBUTYL PURINE DERIVATIVE OR SALT THEREOF 富士フイルム株式会社 2020-01-30 WO disclosed
EP-0352013-B1 Hydroxymethyl cyclobutyl purines SQUIBB & SONS INC (US) 1996-05-01 EP disclosed
US-5369098-A Viricides E. R. SQUIBB & SONS, INC. (US) 1994-11-29 US disclosed
US-5246931-A Triazine-substituted cyclobutane derivatives; viricides; side effect reduction BRISTOL-MYERS SQUIBB COMPANY (US) 1993-09-21 US disclosed
US-5153352-A Viricides and antitumor agent BRISTOL-MYERS SQUIBB COMPANY (US) 1992-10-06 US disclosed
EP-0366059-A2 Carbocyclic nucleoside analogs BRISTOL-MYERS SQUIBB COMPANY (US) 1990-05-02 EP disclosed
JP-H0273072-A HYDROXYMETHYL CYCLOBUTYL PURINE E R SQUIBB & SONS INC 1990-03-13 JP disclosed
EP-0352013-A2 Hydroxymethyl cyclobutyl purines E.R. Squibb & Sons, Inc. (US) 1990-01-24 EP disclosed
EP-0330992-A2 Novel cyclobutane Derivatives, processes for their preparation and pharmaceutical compositions comprising them Nippon Kayaku Kabushiki Kaisha (JP) 1989-09-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295202-A1 CYCLOBUTYL PURINE DERIVATIVE OR SALT THEREOF SLC28A1, SLC20A1, SLC29A1 HPRT1 24/4885ADORA3 14/4885PNP 48/4885
US-12202850-B2 Cyclobutyl purine derivative or salt thereof SLC28A1, SLC20A1, SLC29A1 HPRT1 24/4885ADORA3 14/4885PNP 48/4885
US-20210155644-A1 CYCLOPENTENYL PURINE DERIVATIVE OR SALT THEREOF SLC28A1, SLC20A1, NOX1 HPRT1 143/4885ADORA3 94/4885PNP 103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.